June 15 (Reuters) - Kazia Therapeutics Ltd (KZA) :
- KAZIA ENTERS CLINICAL COLLABORATION WITH CORNELL UNIVERSITY FOR PHASE II CLINICAL STUDY USING PAXALISIB IN COMBINATION WITH KETOGENIC DIET FOR GLIOBLASTOMA
- KAZIA THERAPEUTICS LTD - KAZIA WILL PROVIDE SUPPORT INCLUDING STUDY DRUG AND A FINANCIAL GRANT
- KAZIA - RECRUITMENT TO STUDY IS EXPECTED TO COMMENCE BY END OF CY2021, SUBJECT TO APPROVAL BY INSTITUTIONAL REVIEW BOARDS, FDA, OTHER AUTHORITIES
June 15 (Reuters) - Kazia Therapeutics Ltd (KZA) : KAZIA ENTERS...
Add to My Watchlist
What is My Watchlist?